Claudia Kasserra

Summary

Affiliation: Celgene Corporation
Country: USA

Publications

  1. doi request reprint Effect of vicriviroc with or without ritonavir on oral contraceptive pharmacokinetics: a randomized, open-label, parallel-group, fixed-sequence crossover trial in healthy women
    Claudia Kasserra
    Schering Plough, Merck and Co, Inc, Kenilworth, New Jersey, USA
    Clin Ther 33:1503-14. 2011
  2. pmc Effect of vicriviroc on the QT/corrected QT interval and central nervous system in healthy subjects
    Edward O'Mara
    Merck and Co, Kenilworth, NJ 07033, USA
    Antimicrob Agents Chemother 54:2448-54. 2010
  3. doi request reprint Pharmacokinetic interaction of vicriviroc with other antiretroviral agents: results from a series of fixed-sequence and parallel-group clinical trials
    Claudia Kasserra
    Schering Plough, Merck and Co, Inc, Kenilworth, New Jersey 07033, USA
    Clin Pharmacokinet 50:267-80. 2011
  4. doi request reprint Renal insufficiency has no effect on the pharmacokinetics of vicriviroc in a ritonavir-containing regimen
    Claudia Kasserra
    Schering Plough Research Institute, Kenilworth, New Jersey 07033, USA
    Clin Pharmacokinet 49:397-406. 2010

Collaborators

  • Angela Sansone-Parsons
  • Edward O'Mara
  • Maria Caceres
  • Yuntao Wan
  • Peter Soni
  • Matthew Medlock
  • John Robert Huddlestone
  • Royce Morrison
  • Orrin Devinsky

Detail Information

Publications4

  1. doi request reprint Effect of vicriviroc with or without ritonavir on oral contraceptive pharmacokinetics: a randomized, open-label, parallel-group, fixed-sequence crossover trial in healthy women
    Claudia Kasserra
    Schering Plough, Merck and Co, Inc, Kenilworth, New Jersey, USA
    Clin Ther 33:1503-14. 2011
    ....
  2. pmc Effect of vicriviroc on the QT/corrected QT interval and central nervous system in healthy subjects
    Edward O'Mara
    Merck and Co, Kenilworth, NJ 07033, USA
    Antimicrob Agents Chemother 54:2448-54. 2010
    ....
  3. doi request reprint Pharmacokinetic interaction of vicriviroc with other antiretroviral agents: results from a series of fixed-sequence and parallel-group clinical trials
    Claudia Kasserra
    Schering Plough, Merck and Co, Inc, Kenilworth, New Jersey 07033, USA
    Clin Pharmacokinet 50:267-80. 2011
    ..The aim of this set of studies was to determine what, if any, dose adjustments or monitoring would be required to use vicriviroc in regimens containing the most common antiretroviral agents...
  4. doi request reprint Renal insufficiency has no effect on the pharmacokinetics of vicriviroc in a ritonavir-containing regimen
    Claudia Kasserra
    Schering Plough Research Institute, Kenilworth, New Jersey 07033, USA
    Clin Pharmacokinet 49:397-406. 2010
    ..The present study therefore examined the impact of renal insufficiency on the pharmacokinetics and safety of vicriviroc alone and in the presence of ritonavir, a strong CYP3A4 inhibitor...